Literature DB >> 6101256

Vancomycin therapy in patients with impaired renal function: a nomogram for dosage.

R C Moellering, D J Krogstad, D J Greenblatt.   

Abstract

The relation between vancomycin clearance and renal function was studied in 22 patients with various degrees of renal functional impairment and in four normal volunteers. Clearance of vancomycin and creatinine were highly correlated (r = 0.92) among 17 persons not on dialysis. In five dialysis patients vancomycin clearance averaged 0.086 mL/min . kg of body weight (+/- SEM = 0.025). These relations enabled us to construct a nomogram for vancomycin dosage adjustment (based on a mean steady-state serum vancomycin concentration of 15 micrograms/mL) in patients with various degrees of renal functional impairment.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6101256     DOI: 10.7326/0003-4819-94-3-343

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  62 in total

1.  A clinical view of vancomycin in 1990.

Authors:  W T Siebert
Journal:  Tex Heart Inst J       Date:  1990

2.  The serum vancomycin assay: A test of historic interest.

Authors:  S Shafran; J Conly
Journal:  Can J Infect Dis       Date:  1995-03

3.  Recurrent Staphylococcus aureus bacteremia.

Authors:  A I Hartstein; M E Mulligan; V H Morthland; R Y Kwok
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

Review 4.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

5.  Levels of vancomycin in the cerebral interstitial fluid after severe head injury.

Authors:  Anselmo Caricato; Mariano Pennisi; Aldo Mancino; Gianluca Vigna; Claudio Sandroni; Andrea Arcangeli; Massimo Antonelli
Journal:  Intensive Care Med       Date:  2006-01-24       Impact factor: 17.440

6.  Cost-ineffectiveness of serum vancomycin levels.

Authors:  B A Cunha; S S Mohan; N Hamid; B P McDermott; P Daniels
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-07       Impact factor: 3.267

7.  Protein binding of vancomycin in a patient with immunoglobulin A myeloma.

Authors:  T G Cantú; J D Dick; D E Elliott; R L Humphrey; D M Kornhauser
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

8.  Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies.

Authors:  Dolores Santos Buelga; María del Mar Fernandez de Gatta; Emma V Herrera; Alfonso Dominguez-Gil; María José García
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 9.  Pharmacokinetic optimisation of vancomycin therapy.

Authors:  W G Leader; M H Chandler; M Castiglia
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.